Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Cancers. 2021 Dec 21. pii: cancers14010004. doi: 10.3390/cancers14010004
    Prognostic Significance of Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer.
    Tserpeli V1,  Stergiopoulou D2,  Londra D3,  Giannopoulou L4,  Buderath P5,  Balgkouranidou I6,  Xenidis N7,  Grech C8,  Obermayr E9,  Zeillinger R10,  Pavlakis K11,  Rampias T12,  Kakolyris S13,  Kasimir-Bauer S14,  Lianidou ES15
    Author information
    1Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
    2Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
    3Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
    4Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
    5Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
    6Department of Oncology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
    7Department of Oncology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
    8Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria.
    9Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria.
    10Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria.
    11Pathology Department, IASO Women's Hospital, 15123 Athens, Greece.
    12Basic Research Center, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
    13Department of Oncology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
    14Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
    15Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
    Abstract

    BACKGROUND: Epigenetic alterations in ctDNA are highly promising as a source of novel potential liquid biopsy biomarkers and comprise a very promising liquid biopsy approach in ovarian cancer, for early diagnosis, prognosis and response to treatment.

    METHODS: In the present study, we examined the methylation status of six gene promoters (, , , , and in high-grade serous ovarian cancer (HGSOC). We evaluated the prognostic significance of DNA methylation of these six gene promoters in primary tumors (FFPEs) and plasma cfDNA samples from patients with early, advanced and metastatic HGSOC.

    RESULTS: We report for the first time that the DNA methylation of in plasma cfDNA was significantly correlated with worse PFS ( = 0.045) in advanced stage HGSOC.

    CONCLUSIONS: Our results strongly indicate that epigenetic inactivation could be a predictor of resistance to platinum drugs in ovarian cancer. Our results should be further validated in studies based on a larger cohort of patients, in order to further explore whether the DNA methylation of promoter could serve as a potential prognostic DNA methylation biomarker and a predictor of resistance to platinum-based chemotherapy in ovarian cancer.


    KEYWORDS: DNA methylation, Schlaffen11, high-grade serous ovarian cancer, liquid biopsy, methylation specific PCR, plasma cell-free DNA, prognostic biomarker, progression free survival

    Publikations ID: 35008168
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt